As Hims prepares for peptides launch, Wall Street cautious on prospects this year
Reuters reports Hims & Hers Health plans to sell legally available peptides in 2026, including NAD+, sermorelin and glutathione, after its quarterly results. Analysts told Reuters the 2025 revenue impact is likely limited because NAD+ is already available and FDA rulemaking for other peptides could take about a year. Peptides market size cited at $2.2B to $3.3B.
How this was made
The 30-second read
Why it matters
Investors are weighing whether the first wave of peptides (notably NAD+) meaningfully changes near-term revenue versus waiting for FDA final rulemaking and potential approvals for additional peptides.
Market read
The market is cautious because the initial peptide offering is tied to products already legal, while the bigger growth lever depends on FDA outcomes that may take about a year.
What to watch
The article notes possible FDA enforcement discretion for interim manufacturing; if that materializes, earlier-than-expected launches could change the near-term revenue curve despite Street skepticism.
Background
Hims is preparing to offer certain legally available peptides in 2026 amid ongoing FDA review and debate over evidence for loosening compounding restrictions.
Ticker impact
Hims said it will sell legally available peptides in 2026, but analysts expect the NAD+ offering to have limited impact on this year’s revenue growth.
Likely modest, sentiment-driven moves rather than a sustained re-rating until FDA guidance or approvals expand the addressable peptide lineup.
The article’s incremental facts are management’s 2026 peptide plan and Street skepticism that NAD+ changes the revenue trajectory this year; the next major catalyst is FDA final rulemaking and potential interim enforcement discretion.
Market effects
Highlights regulatory uncertainty around compounding peptides and the market’s focus on FDA rulemaking timelines versus already-available products.
Primarily US healthcare/telehealth sentiment; no specific regional spillover beyond US regulatory framing.
Limited direct global impact, but reinforces broader global scrutiny of non-FDA-approved peptide markets.
Counterpoint
Even if NAD+ is already available, Hims’ owned compounding/manufacturing capacity and subscriber base could still translate into share gains and higher margins before FDA expands the category.
Key entities
- companyHims & Hers Health
Telehealth and compounding pharmacy company planning a 2026 launch of legally available peptides and conducting stability/validation testing for BPC-157.
- regulatorFDA
Ongoing review and rulemaking process that determines whether additional peptides can be compounded and sold by US pharmacies.
- investorCedar Grove Capital Management (Paul Cerro)
Said there is no ‘release the floodgates’ demand for already-available peptides like NAD+.
- investorDocShah Financial (Raul Shah)
Argued Hims does not need to rush launches before FDA finalizes guidance and expects long-term revenue contribution.
